ANELLOVECTOR

Serial Number 98118232
Registration 7469817
700

Registration Progress

Application Filed
Aug 4, 2023
Under Examination
Feb 27, 2024
Approved for Publication
Jan 2, 2024
Published for Opposition
Jan 2, 2024
Registered
Aug 6, 2024

Trademark Image

ANELLOVECTOR

Basic Information

Serial Number
98118232
Registration Number
7469817
Filing Date
August 4, 2023
Registration Date
August 6, 2024
Published for Opposition
January 2, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 6, 2024
Registration
Registered
Classes
005

Rights Holder

Ring Therapeutics, Inc.

03
Address
140 First Street
Cambridge, MA 02141

Ownership History

Ring Therapeutics, Inc.

Original Applicant
03
Cambridge, MA

Ring Therapeutics, Inc.

Owner at Publication
03
Cambridge, MA

Ring Therapeutics, Inc.

Original Registrant
03
Cambridge, MA

Legal Representation

Attorney
Christina M. Licursi

USPTO Deadlines

Next Deadline
1656 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240806)
Due Date
August 06, 2030
Grace Period Ends
February 06, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

19 events
Date Code Type Description Documents
Aug 6, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Aug 6, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jul 3, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jul 3, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Mar 29, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Mar 7, 2024 IUAF S USE AMENDMENT FILED Loading...
Mar 29, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 7, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Feb 27, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 2, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 2, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 26, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Dec 26, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Dec 26, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Dec 13, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 29, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 28, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 11, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 8, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Encapsulated nucleic acid agents for medical use; pharmaceutical preparations for use in the prevention, diagnosis and treatment of disease, namely, rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune/autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in gene therapy
First Use Anywhere: Oct 11, 2023
First Use in Commerce: Oct 11, 2023

Classification

International Classes
005